Search Results

-sparing adjuvant therapy in patients with node-positive disease. The authors' current selection criteria for fertility-sparing radical trachelectomy are listed in Table 1 . Patients are selected for a laparoscopic vaginal approach (Dargent operation) if they are

noninferiority of 3 months of adjuvant therapy in the overall population, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Colon Cancer include the recommendation of 3 to 6 months of adjuvant chemotherapy based on risk stratification. 8

unavailable (n=66). Eight clinical pathways based on ER, PR, and HER2 status were developed to guide treatment, considerations, evidence-based neoadjuvant and adjuvant therapy, and survivorship care. Pathways, with associated educational webinars and links to

/CTSU 49907 [abstract] . J Clin Oncol 2008 ; 26 ( Suppl 1 ): Abstract 507 . 31 Ravdin PM Siminoff LA Davis GJ . Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer . J Clin Oncol 2001 ; 19

Cancers allowed the authors to create a system that could be used to examine quality across the spectrum of CRC care, from diagnosis through neoadjuvant therapy, surgery, adjuvant therapy, and surveillance or end-of-life care. The tool had important

category 1 recommendations for adjuvant therapy. 9 Despite these consensus recommendations, studies have shown that, outside of the clinical trial setting, many patients do not go on to receive adjuvant chemotherapy. 10 – 13 Variables shown to affect the

into the perinodal tissues beyond the lymph node capsule—extranodal extension (ENE)—after SNB with a positive result would allow a more appropriate use of adjuvant therapy for those most likely to benefit, while also minimizing the morbidity for

fluorouracil and folinic acid in B2 colon cancer . J Clin Oncol 1999 ; 17 : 1356 – 1363 . 54. Gill S Loprinzi CL Sargent DJ . Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much

decision regarding adjuvant therapy. 37 , 92 Seven studies were found to have clinical utility evidence ( Figure 3 , supplemental eTable 2 ) on Decipher after prostatectomy, 36 , 55 – 57 , 76 – 78 and none were found on its use after a positive biopsy

NSABP B-31 and NCCTG N9831 trials of adjuvant therapy in breast cancer. From Romond et al. 19 ; with permission. HER2 Testing: Summary of Clinical Issues The use of HER2 tumor biomarker status in clinical decision-making ( Figure 1 ) has been limited by